Identification of human papillomavirus type 16 integration sites in high-grade precancerous cervical lesions

Gynecologic Oncology

Volumn 113, Issue 1, 2009, Pages 120-127

  Matovina, Mihaela ^a   Sabol, Ivan ^a   Grubišić, Goran ^b   Gašperov, Nina Milutin ^a   Grce, Magdalena ^a  

^a RUDER BO KOVI INSTITUTE   (Croatia)

^b SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

Author keywords

Common fragile sites (CFS); Detection of integrated papillomavirus sequences (DIPS); E1 E2 amplification; Human papillomaviruses (HPV); Polymerase chain reaction (PCR); Viral genome integration

Indexed keywords

CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 1; CELL DNA; CELL PROTEIN; GLYCOPROTEIN E1; GLYCOPROTEIN E2; NECTIN 1; VIRUS DNA;

AMPLICON; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CHROMOSOME FRAGILE SITE; CONTROLLED STUDY; DISEASE SEVERITY; DNA INTEGRATION; DNA SEQUENCE; FEMALE; GENE AMPLIFICATION; GENE IDENTIFICATION; GENE LOCATION; GENE SEQUENCE; GENOME ANALYSIS; HOST CELL; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; NONHUMAN; POLYMERASE CHAIN REACTION; PRECANCER; PRIORITY JOURNAL; UTERINE CERVIX TUMOR; VIRUS GENOME;

ADOLESCENT; ADULT; DNA, VIRAL; DNA-BINDING PROTEINS; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; MIDDLE AGED; ONCOGENE PROTEINS, VIRAL; PRECANCEROUS CONDITIONS; UTERINE CERVICAL NEOPLASMS; VIRUS INTEGRATION; YOUNG ADULT;

EID: 62549166628     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.12.004     Document Type: Article

References (49)

1. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Human Papillomaviruses 90 (2007), WHO Press 1-689
2. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189 (1999) 12-19
3. Bosch F.X., Manos M.M., Muñoz N., Sherman M., Jansen A.M., Peto J., et al., IBSCC Study group. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J. Natl. Cancer Inst. 87 (1995) 796-802
4. Jeon S., Allen-Hoffmann B.L., and Lambert P.F. Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells. J. Virol. 69 (1995) 2989-2997
5. Romanczuk H., and Howley P. Disruption of either the E1 or the E2 regulatory gene of human papillomavirus type 16 increases viral immortalization capacity. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 3159-3163
6. Dowhanick J.J., McBride A.A., and Howley P.M. Suppression of cellular proliferation by the papillomavirus E2 protein. J. Virol. 69 (1995) 7791-7797
7. Jeon S., and Lambert P.F. Integration of human papillomavirus type 16 DNA into the human genome leads to increased stability of E6 and E7 mRNAs: implications for cervical carcinogenesis. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 1654-1658
8. von Knebel Doeberitz M., Bauknecht T., Bartsch D., and zur Hausen H. Influence of chromosomal integration on glucocorticoid-regulated transcription of growth-stimulating papillomavirus genes E6 and E7 in cervical carcinoma cells. Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 1411-1415
9. Bechtold V., Beard P., and Raj K. Human papillomavirus type 16 E2 protein has no effect on transcription from episomal viral DNA. J. Virol. 77 (2003) 2021-2028
10. Wentzensen N., Vinokurova S., and von Knebel Doeberitz M. Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract. Cancer Res. 64 (2004) 3878-3884
11. Thorland E.C., Myers S.L., Persing D.H., Sarkar G., McGovern R.M., Gostout B.S., et al. Human papillomavirus type 16 integrations in cervical tumors frequently occur in common fragile sites. Cancer Res. 60 (2000) 5916-5921
12. Smith D.I., Huang H., and Wang L. Common fragile sites and cancer. Int. J. Oncol. 12 (1998) 187-196
13. Ljubojević N., Babić S., Audy-Jurković S., Ovanin-Rakić A., Jukić S., Babić D., et al. Improved national Croatian diagnostic and therapeutic guidelines for premalignant lesions of the uterine cervix with some cost-benefit aspects. Coll. Antropol. 25 (2001) 467-474
14. Grce M., Husnjak K., Bozikov J., Magdic L., Zlacki M., Lukac J., et al. Evaluation of genital human papillomavirus infections by polymerase chain reaction among Croatian women. Anticancer Res. 21 (2001) 579-584
15. Ovanin-Rakic A., Pajtler M., Stankovic T., Audy-Jurkovic S., Ljubojevic N., Grubisic G., et al. [Classification of cervical cytological smears "Zagreb 2002". Modification of the classification "Zagreb 1990" and "NCI Bethesda 2001".]. Gynaecol. Perinatol. 12 (2003) 148-153 [In Croatian]
16. Luft F., Klaes R., Nees M., Durst M., Heilmann V., Melsheimer P., et al. Detection of integrated papillomavirus sequences by ligation-mediated PCR (DIPS-PCR) and molecular characterization in cervical cancer cells. Int. J. Cancer 92 (2001) 9-17
17. Yoshinouchi M., Hongo A., Nakamura K., Kodama J., Itoh S., Sakai H., et al. Analysis by multiplex PCR of the physical status of human papillomavirus type 16 DNA in cervical cancers. J. Clin. Microbiol. 37 (1999) 3514-3517
18. Lukaszuk K., Liss J., Wozniak I., Emerich J., and Wojcikowski C. Human papillomavirus type 16 status in cervical carcinoma cell DNA assayed by multiplex PCR. J. Clin. Microbiol. 41 (2003) 608-612
19. Kalantari M., Blennow E., Hagmar B., and Johansson B. Physical state of HPV16 and chromosomal mapping of the integrated form in cervical carcinomas. Diagn. Mol. Pathol. 10 (2001) 46-54
20. Klaes R., Woerner S.M., Ridder R., Wentzensen N., Duerst M., Schneider A., et al. Detection of high-risk cervical intraepithelial neoplasia and cervical cancer by amplification of transcripts derived from integrated papillomavirus oncogenes. Cancer Res. 59 (1999) 6132-6136
21. Badaracco G., Venuti A., Sedati A., and Marcante M.L. HPV16 and HPV18 in genital tumors: significantly different levels of viral integration and correlation to tumor invasiveness. J. Med. Virol. 67 (2002) 574-582
22. Cullen A.P., Reid R., Campion M., and Lorincz A.T. Analysis of the physical state of different human papillomavirus DNAs in intraepithelial and invasive cervical neoplasm. J. Virol. 65 (1991) 606-612
23. Hopman A.H., Smedts F., Dignef W., Ummelen M., Sonke G., Mravunac M., et al. Transition of high-grade cervical intraepithelial neoplasia to micro-invasive carcinoma is characterized by integration of HPV 16/18 and numerical chromosome abnormalities. J. Pathol. 202 (2004) 23-33
24. Gallo G., Bibbo M., Bagella L., Zamparelli A., Sanseverino F., Giovagnoli M.R., et al. Study of viral integration of HPV-16 in young patients with LSIL. J. Clin. Pathol. 56 (2003) 532-536
25. Watts K. Sequence variation and physical status of human papillomavirus type 16 cervical cancer isolates from Australia and New Caledonia. Int. J. Cancer 97 (2002) 868-874
26. Peitsaro P., Johansson B., and Syrjanen S. Integrated human papillomavirus type 16 is frequently found in cervical cancer precursors as demonstrated by a novel quantitative Real-Time PCR technique. J. Clin. Microbiol. 40 (2002) 886-891
27. Nayar R., and Solomon D. Second edition of 'The Bethesda System for reporting cervical cytology' - atlas, website, and Bethesda interobserver reproducibility project. Cytojournal 1 (2004) 4
28. Yu T., Ferber M.J., Cheung T.H., Chung T.K., Wong Y.F., and Smith D.I. The role of viral integration in the development of cervical cancer. Cancer Genet. Cytogenet. 158 (2005) 27-34
29. Thorland E.C., Myers S.L., Gostout B.S., and Smith D.I. Common fragile sites are preferential targets for HPV16 integrations in cervical tumors. Oncogene 22 (2003) 1225-1237
30. Tsuchiya A., Sakamoto M., Yasuda J., Chuma M., Ohta T., Ohki M., et al. Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1β as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am. J. Pathol. 163 (2003) 2503-2512
31. Hoshino T., Sakisaka T., Baba T., Yamada T., Kimura T., and Takai Y. Regulation of E-cadherin endocytosis by nectin through afadin, Rap1, and p120ctn. J. Biol. Chem. 280 (2005) 24095-24103
32. Krummenacher C., Baribaud F., Ponce de Leon M., Baribaud I., Whitbeck J.C., Xu R., et al. Comparative usage of herpesvirus entry mediator A and nectin-1 by laboratory strains and clinical isolates of herpes simplex virus. Virology 322 (2004) 286-299
33. Hampton G.M., Penny L.A., Baergen R.N., Larson A., Brewer C., Liao S., et al. Loss of heterozygosity in cervical carcinoma: subchromosomal localization of a putative tumor-suppressor gene to chromosome 11q22-q24. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 6953-6957
34. Bethwaite P.B., Koreth J., Herrington C.S., and McGee J.O. Loss of heterozygosity occurs at the D11S29 locus on chromosome 11q23 in invasive cervical carcinoma. Br. J. Cancer 71 (1995) 814-818
35. Mullokandov M.R., Kholodilov N.G., Atkin N.B., Burk R.D., Johnson A.B., and Klinger H.P. Genomic alterations in cervical carcinoma: losses of chromosome heterozygosity and human papilloma virus tumor status. Cancer Res. 56 (1996) 197-205
36. Kersemaekers A.M., Hermans J., Fleuren G.J., and van de Vijver M.J. Loss of heterozygosity for defined regions on chromosomes 3, 11 and 17 in carcinomas of the uterine cervix. Br. J. Cancer 77 (1998) 192-200
37. Lazo P. The molecular genetics of cervical carcinoma. Br. J. Cancer 80 (1999) 2008-2018
38. Tong Y., Quirion R., and Shen S.H. Cloning and characterization of a novel mammalian PP2C isozyme. J. Biol. Chem. 273 (1998) 35282-35290
39. Leung-Hagesteijn C., Mahendra A., Naruszewicz I., and Hannigan G.E. Modulation of integrin signal transduction by ILKAP, a protein phosphatase 2C associating with the integrin-linked kinase, ILK1. EMBO J. 20 (2001) 2160-2170
40. Narayan G., Pulido H.A., Koul S., Lu X.Y., Harris C.P., Yeh Y.A., et al. Genetic analysis identifies putative tumor suppressor sites at 2q35-q36.1 and 2q36.3-q37.1 involved in cervical cancer progression. Oncogene 22 (2003) 3489-3499
41. Laplante J.M., O'Rourke F., Lu X., Fein A., Olsen A., and Feinstein M.B. Cloning of human Ca2+ homoeostasis endoplasmic reticulum protein (CHERP): regulated expression of antisense cDNA depletes CHERP, inhibits intracellular Ca2+ mobilization and decreases cell proliferation. Biochem. J. 348 (2000) 189-199
42. O'Rourke F.A., LaPlante J.M., and Feinstein M.B. Antisense-mediated loss of calcium homoeostasis endoplasmic reticulum protein (CHERP; ERPROT213-21) impairs Ca2+ mobilization, nuclear factor of activated T-cells (NFAT) activation and cell proliferation in Jurkat T-lymphocytes. Biochem. J. 373 (2003) 133-143
43. Wirth T., Soeth E., Czubayko F., and Juhl H. Inhibition of endogenous carcinoembryonic antigen (CEA) increases the apoptotic rate of colon cancer cells and inhibits metastatic tumor growth. Clin. Exp. Metastasis 19 (2002) 155-160
44. Baczynska D., Wietrzyk J., Madej J., Krop-Watorek A., Dabrowska A., Widerak K., et al. The tumorigenic potential of human CX-1 colon adenocarcinoma cells depends on carcinoembryonic antigen (CEACAM5) expression. Cell. Mol. Biol. Lett. 8 (2003) 471-486
45. Blumenthal R.D., Hansen H.J., and Goldenberg D.M. Inhibition of adhesion, invasion, and metastasis by antibodies targeting CEACAM6 (NCA-90) and CEACAM5 (carcinoembryonic antigen). Cancer Res. 65 (2005) 8809-8817
46. Andersson P., McGuire J., Rubio C., Gradin K., Whitelaw M.L., Pettersson S., et al. A constitutively active dioxin/aryl hydrocarbon receptor induces stomach tumors. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 9990-9995
47. Yang X., Liu D., Murray T.J., Mitchell G.C., Hesterman E.V., Karchner S.I., et al. The aryl hydrocarbon receptor constitutively represses c-myc transcription in human mammary tumor cells. Oncogene 24 (2005) 7869-7881
48. Zhu L., Hu J., Lin D., Whitson R., Itakura K., and Chen Y. Dynamics of the Mrf-2 DNA-binding domain free and in complex with DNA. Biochemistry 40 (2001) 9142-9150
49. Watanabe M., Layne M.D., Hsieh C.M., Maemura K., Gray S., Lee M.E., et al. Regulation of smooth muscle cell differentiation by AT-rich interaction domain transcription factors Mrf2α and Mrf2β. Circ. Res. 91 (2002) 382-389